← Back to Clinical Trials
Recruiting NCT05830266

NCT05830266 Mother-infant Bonding in the Brain: a Mindfulness-based Intervention

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05830266
Status Recruiting
Phase
Sponsor Tilburg University
Condition Postpartum Depression
Study Type INTERVENTIONAL
Enrollment 64 participants
Start Date 2023-07-01
Primary Completion 2026-07

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
"Mindful with your Baby" group-based therapist-guided intervention"Mindful with your baby" self-guided online intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 64 participants in total. It began in 2023-07-01 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study investigates the effectiveness of the mindfulness-based intervention "Mindful with your Baby" in women with babies between 5-9 months postpartum who experience heightened levels of postpartum depression, anxiety and/or parental stress. The intervention "Mindful with your Baby" is one of the very few interventions for maternal postnatal mental health issues that takes the bond between mother and infant into account. It is hypothesized that the "Mindful with your Baby" intervention will reduce levels of postpartum depression, anxiety and parental stress, and improve mother-infant behavioral interaction and increase neural synchrony between mother and infant brains.

Eligibility Criteria

Inclusion Criteria: * Pregnant women (18+y). * First antenatal visit \< 12 weeks. * Score above cut off on the Edinburgh Postnatal Depression Scale (EPDS), the anxiety subscale of the Symptom Checklist (SCL-90) and/or the Parental Stress Questionnaire (PSQ) at 8-10 weeks postpartum. * Dutch-speaking or understanding Dutch. Exclusion Criteria: * Gemelli pregnancy (or higher order pregnancy). * Known endocrine disorder before pregnancy (diabetes-I, Rheumatoid arthritis). * Severe psychiatric disease (schizophrenia, borderline or bipolar disorder). * HIV. * Drug or alcohol addiction problems. * Any other disease resulting in treatment with drugs that are potentially adverse for the fetus and need careful follow-up during pregnancy. * No access to the internet.

Contact & Investigator

Central Contact

Marion I van den Heuvel, PhD

✉ m.i.vdnheuvel@tilburguniversity.edu

📞 +31134664085

Principal Investigator

Marion I van den Heuvel, PhD

PRINCIPAL INVESTIGATOR

Tilburg University

Frequently Asked Questions

Who can join the NCT05830266 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Postpartum Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05830266 currently recruiting?

Yes, NCT05830266 is actively recruiting participants. Contact the research team at m.i.vdnheuvel@tilburguniversity.edu for enrollment information.

Where is the NCT05830266 trial being conducted?

This trial is being conducted at Tilburg, Netherlands.

Who is sponsoring the NCT05830266 clinical trial?

NCT05830266 is sponsored by Tilburg University. The principal investigator is Marion I van den Heuvel, PhD at Tilburg University. The trial plans to enroll 64 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology